Compare Stocks: NGNE, VRDN, ADMA, and AUPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.72 -2.1%	$9.43	$7.21 ▼ $20.46	$2.18B	0.7	3.09 million shs	2.79 million shs
AUPH Aurinia Pharmaceuticals	$15.83 -0.8%	$16.01	$10.90 ▼ $19.25	$2.11B	1.6	783,421 shs	813,423 shs
NGNE Neurogene	$25.65 -3.4%	$34.84	$15.93 ▼ $43.66	$513.28M	1.7	310,825 shs	401,639 shs
VRDN Viridian Therapeutics	$19.40 +2.2%	$22.03	$13.18 ▼ $34.29	$2.20B	1.11	1.75 million shs	1.52 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+3.62%	+1.46%	+8.60%	-35.42%
AUPH Aurinia Pharmaceuticals	0.00%	-3.71%	-1.80%	+1.41%	+38.86%
NGNE Neurogene	0.00%	-9.40%	-31.80%	-27.42%	+42.66%
VRDN Viridian Therapeutics	0.00%	-5.23%	-15.51%	0.00%	-8.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.72 -2.1%	$9.43	$7.21 ▼ $20.46	$2.18B	0.7	3.09 million shs	2.79 million shs
AUPH Aurinia Pharmaceuticals	$15.83 -0.8%	$16.01	$10.90 ▼ $19.25	$2.11B	1.6	783,421 shs	813,423 shs
NGNE Neurogene	$25.65 -3.4%	$34.84	$15.93 ▼ $43.66	$513.28M	1.7	310,825 shs	401,639 shs
VRDN Viridian Therapeutics	$19.40 +2.2%	$22.03	$13.18 ▼ $34.29	$2.20B	1.11	1.75 million shs	1.52 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+3.62%	+1.46%	+8.60%	-35.42%
AUPH Aurinia Pharmaceuticals	0.00%	-3.71%	-1.80%	+1.41%	+38.86%
NGNE Neurogene	0.00%	-9.40%	-31.80%	-27.42%	+42.66%
VRDN Viridian Therapeutics	0.00%	-5.23%	-15.51%	0.00%	-8.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	92.04% Upside
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	11.60% Upside
NGNE Neurogene	3.00	Buy	$83.67	226.19% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.69	99.44% Upside

Current Analyst Ratings Breakdown

Latest NGNE, VRDN, ADMA, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	NGNE Neurogene	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/14/2026	VRDN Viridian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/12/2026	NGNE Neurogene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$69.00 ➝ $81.00
8/12/2026	NGNE Neurogene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$180.00 ➝ $166.00
8/12/2026	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$70.00 ➝ $65.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.27	$0.65 per share	14.86	$2.01 per share	4.84
AUPH Aurinia Pharmaceuticals	$283.05M	7.44	$1.01 per share	15.62	$4.41 per share	3.59
NGNE Neurogene	$930K	551.89	N/A	N/A	$17.10 per share	1.50
VRDN Viridian Therapeutics	$70.85M	31.02	N/A	N/A	$6.18 per share	3.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.89	11.44	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	6.91	14.66	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-45.10%	-41.00%	11/12/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest NGNE, VRDN, ADMA, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
NGNE Neurogene	N/A	10.65	10.64
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AUPH Aurinia Pharmaceuticals	36.83%
NGNE Neurogene	52.37%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
AUPH Aurinia Pharmaceuticals	10.40%
NGNE Neurogene	11.68%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
AUPH Aurinia Pharmaceuticals	128	133.05 million	119.21 million	Optionable
NGNE Neurogene	131	20.01 million	17.67 million	Optionable
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

NGNE, VRDN, ADMA, and AUPH Headlines

Recent News About These Companies

Emergent Biosolutions (NYSE:EBS) and Viridian Therapeutics (NASDAQ:VRDN) Head to Head Contrast

2 hours ago | americanbankingnews.com

Wall Street Zen Downgrades Viridian Therapeutics (NASDAQ:VRDN) to Strong Sell

October 4 at 1:07 AM | americanbankingnews.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Dropped to Strong Sell by Wall Street Zen

October 4 at 1:05 AM | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% - Here's Why

October 1 at 12:39 PM | marketbeat.com

Viridian Therapeutics stock weighs Lumvoa uptake against losses

September 30, 2026 | ad-hoc-news.deA

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 30, 2026 | americanbankingnews.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

September 30, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Upgraded to Sell at Wall Street Zen

September 26, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Viridian Therapeutics (NASDAQ:VRDN) to "Sell"

September 26, 2026 | marketbeat.com

Bank of America Corp DE Makes New $17.35 Million Investment in Viridian Therapeutics, Inc. $VRDN

September 25, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)

September 23, 2026 | theglobeandmail.com

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

September 22, 2026 | finance.yahoo.com

Viridian Therapeutics: Two Products, One Commercial Buildout

September 17, 2026 | seekingalpha.com

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13, 2026 | marketbeat.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8, 2026 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NGNE, VRDN, ADMA, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.72 -0.21 (-2.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.80 +0.08 (+0.82%)

As of 10/2/2026 07:30 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Aurinia Pharmaceuticals NASDAQ:AUPH

$15.83 -0.12 (-0.75%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$15.82 -0.01 (-0.03%)

As of 10/2/2026 07:30 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Neurogene NASDAQ:NGNE

$25.65 -0.90 (-3.39%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.62 -0.04 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Viridian Therapeutics NASDAQ:VRDN

$19.40 +0.41 (+2.16%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$19.46 +0.07 (+0.34%)

As of 10/2/2026 07:35 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGNE, VRDN, ADMA, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGNE, VRDN, ADMA, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGNE, VRDN, ADMA, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NGNE, VRDN, ADMA, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

Aurinia Pharmaceuticals NASDAQ:AUPH

Neurogene NASDAQ:NGNE

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NGNE, VRDN, ADMA, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NGNE, VRDN, ADMA, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NGNE, VRDN, ADMA, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NGNE, VRDN, ADMA, and AUPH Company Descriptions

ADMA Biologics NASDAQ:ADMA

Aurinia Pharmaceuticals NASDAQ:AUPH

Neurogene NASDAQ:NGNE

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools